SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today  announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Regulatory Milestone in Saudi Arabia Cuprina’s 49%-own ...

SINGAPORE, March 11, 2026 (GLOBE NEWSWIRE) -- Cuprina Holdings (Cayman) Limited (Nasdaq: CUPR) (“Cuprina” or “the Company”), a biomedical company developing and marketing products for the chronic wounds, infertility, medical waste recycling, and cosmeceuticals sectors, today announced several strategic business developments, including a significant regulatory classification in Saudi Arabia and the expansion of its Medical and Scientific Advisory Board. Regulatory Milestone in Saudi Arabia Cuprina’s 49%-owne ...

Core Viewpoint - Cuprina Holdings reported a decrease in revenue and an increase in net loss for the first half of 2025, but highlighted significant advancements in product diversification and geographic expansion [2]. Financial Performance - Revenue for the six months ended June 30, 2025, was $18.04 million, down 40% from $30.18 million in the same period last year, primarily due to lower sales of cosmeceutical and MEDIFLY MDT products [9]. - Gross profit was $302, with a gross margin declining to 1.7% from 44.8% year-over-year, reflecting fixed production costs amid reduced sales volume [9]. - Operating expenses increased by 163% year-over-year to $1,559,535, driven by higher professional fees for capital raising and consultancy [10]. - Net loss for the period was $1,528,121, or $(0.08) per share, compared to a net loss of $518,238, or $(0.03) per share, for the same period in 2024 [10]. - Cash and cash equivalents at June 30, 2025, were $3,216,540, supported by IPO proceeds, compared to $85,622 at December 31, 2024 [11]. Diversification and Expansion Achievements - In May 2025, the company completed construction of an IVF media production facility in Singapore, which is expected to commence commercial sales by Q4 2026 upon regulatory approval [3]. - Cuprina MENA Co. Ltd, a 49%-owned associate, set up a laboratory in Saudi Arabia for manufacturing MEDIFLY MDT products, with plans to begin supplying these products in the MENA region after regulatory approval [4]. - The company secured an FDA-approved license to market medical maggots in the U.S. in July 2025 [5]. - Cuprina obtained exclusive licensing rights to Southeast Asia's first medical waste recycling technology, which aims to transition from incineration to a sustainable model [6]. - A Memorandum of Understanding was signed with Singapore Biowaste Solutions Pte Ltd to integrate Cuprina's medical waste recycling technology into existing waste management facilities [7]. - In November 2025, a joint venture agreement was signed with Aiodine Laboratory to develop and market an iodine-based disinfectant solution for wound treatment [8]. Strategic Initiatives for 2026 - The company anticipates 2026 to be its most active commercial year, with multiple revenue streams expected to advance in parallel [14]. - Growth is projected to be driven by the MEDIFLY MDT business, with expansion into new clinical markets and increased hospital adoption, particularly in the Middle East [14]. - Cuprina plans to commercialize its medical waste recycling technology in partnership with SBS, aiming for recurring revenue [15]. - The company will also advance its amphibian collagen platform through human clinical trials to evaluate its efficacy in wound healing [15]. - To support these initiatives, Cuprina aims to strengthen its organizational leadership and internal capabilities by onboarding top talent and collaborating with industry experts [16]. - Total revenue for 2026 is projected to be between $1.0 million and $1.5 million [17].

Core Viewpoint - Cuprina Holdings has received a noncompliance notice from Nasdaq due to its closing bid price falling below the required minimum of $1 per share for 30 consecutive business days [1]. Compliance and Listing Requirements - The company has a compliance period of 180 calendar days to regain compliance with Nasdaq's minimum bid price requirement [2]. - If the closing bid price reaches at least $1 for ten consecutive business days during this period, Nasdaq will confirm compliance and close the matter [2]. - Should the company fail to regain compliance, it may qualify for an additional 180-day period by meeting other listing requirements, potentially including a reverse stock split [3]. Current Trading Status - The notification does not result in immediate delisting, and Cuprina's shares will continue to trade under the symbol "CUPR" [4]. - The company is actively evaluating options to regain compliance and is committed to meeting Nasdaq's continued listing requirements [4]. Company Overview - Cuprina Holdings is a Singapore-based biomedical company focused on developing products for chronic wounds, infertility, and cosmeceuticals [5].

Core Viewpoint - Cuprina Holdings has entered a joint venture with Aiodine Laboratory to develop and market a novel iodine-based disinfectant solution aimed at treating chronic and acute wounds, as well as other antiseptic applications [1][2]. Company Overview - Cuprina Holdings is a biomedical company focused on products for chronic wounds, infertility, and cosmeceuticals [1]. - Aiodine Laboratory specializes in advanced iodine formulations for health, safety, and hygiene [7]. Joint Venture Details - The joint venture will focus on developing an antiseptic wound care formulation, disinfectants, and daily home-use antiseptics, with plans to evaluate additional applications in personal care, oral hygiene, and veterinary uses [2]. - Cuprina will handle global sales strategies, marketing campaigns, and distribution networks, while Aiodine will provide its proprietary iodine technology and technical expertise [3]. Product Efficacy - The iodine-based solution works by penetrating pathogens and damaging their structures, leading to their destruction [4]. - A study published in Wounds International showed significant wound healing and reduced infection in three out of four patients treated with the solution, indicating its potential safety and effectiveness compared to existing wound care solutions [4]. Market Potential - The global wound care market was valued at approximately US$21 billion in 2024 and is projected to reach US$36 billion by 2032 [5]. - The antiseptics and disinfectants market is expected to exceed US$48 million by 2027 [5].

Core Insights - Cuprina Holdings has signed a Memorandum of Understanding (MOU) with Singapore Biowaste Solutions to explore the integration of its medical waste recycling technology into SBS's waste management facility in Singapore [1][2][3] Company Overview - Cuprina Holdings is a biomedical company focused on developing and marketing products for chronic wounds, infertility, and cosmeceuticals [1][6] - Singapore Biowaste Solutions is recognized as Singapore's most advanced provider for biomedical waste disposal and management [7] Collaboration Details - The collaboration aims to reduce reliance on incineration and landfilling, enhance recycling efficiency, and unlock new revenue streams from recycled materials [2][5] - Cuprina will provide technical expertise, training, and support for a feasibility study and pilot program at SBS's facility [3][4] - SBS will contribute operational data, facility access, and regulatory support to ensure compliance with Singapore's environmental standards [4] Technology and Innovation - Cuprina's technology involves a high-temperature steam process known as autoclaving, which sterilizes, decontaminates, and recycles plastic-based medical waste into high-value resins [3] - This technology has been developed under the oversight of the United Nations Industrial Development Organization (UNIDO) and the Global Environment Facility (GEF) [3] Future Prospects - The companies plan to develop revenue-sharing models for the integrated process and explore expansion opportunities across Southeast Asia [5] - Cuprina's CEO expressed optimism that the integrated recycling technology could secure necessary regulatory approvals and commence operations by the end of 2026 [5]

Core Points - Cuprina Holdings (Cayman) Limited is a biomedical and biotechnology company focused on developing products for chronic wound management, infertility, and cosmeceuticals for health and beauty [1][6] - The company will present at the Skyline Signature Series™ on October 8, 2025, at 11:00 AM ET, allowing investors to engage in real-time Q&A [1][2][3] Event Details - Event Name: Skyline Signature Series™ [3] - Date: October 8, 2025 [3] - Time: 11:00 AM ET [3] - Registration Link: https://us02web.zoom.us/webinar/register/WN_wWWf2nr8QZmKgzx7IaKrXA/registration [3] About Skyline Corporate Communications Group - Skyline Corporate Communications Group, LLC provides investor relations services and ensures a high-quality audience for public companies through careful vetting [4][5] - The firm has experience in strategic messaging and investor communications for public corporations across various industries [5]

Core Insights - Cuprina Holdings has secured exclusive licensing rights for Southeast Asia's first medical waste recycling technology, developed under the oversight of UNIDO and GEF, aimed at improving environmental management in the region [1][2][4] - The new technology utilizes advanced high-temperature steam treatment to sterilize and recycle medical waste, particularly plastic materials, contrasting with traditional incineration methods that produce toxic emissions [3][4] - The company plans to establish Singapore as the first hub for this technology outside of China, targeting significant growth opportunities in Southeast Asia as governments tighten environmental regulations [5] Company Overview - Cuprina Holdings is a biomedical and biotechnology company focused on developing products for chronic wound management and the health and beauty sectors [7] - The company aims to lead the transition from incineration to sustainable waste management practices, enhancing public health and environmental protection while creating long-term shareholder value [7] Industry Context - The global medical waste management market was valued at USD 34.06 billion in 2023 and is projected to reach USD 59.42 billion by 2030, growing at an annual rate of 8%, with Asia-Pacific identified as the fastest-growing region [6]

Core Viewpoint - Cuprina Holdings reaffirms its operational stability and commitment to advancing its biotechnology pipeline amidst recent stock volatility, emphasizing transparency and long-term value for stakeholders [2][3][4]. Company Operations - Cuprina is a fully operational and legally compliant biotechnology company focused on biotherapeutic solutions [2]. - The company is executing its business plan effectively since its Initial Public Offering earlier this year [3]. - Cuprina is exploring potential joint ventures and mergers & acquisitions to enhance chronic wound management products [4]. Financial and Market Position - The company has not observed any operational reasons for the recent stock price volatility and reports no material adverse events [3]. - None of the initial shareholders or founding team members have sold their stock recently, indicating confidence in the company's mission and growth potential [4]. Future Developments - Cuprina is on track with its operational and regulatory milestones, including the submission of FDA clearance for its medical maggot therapy and expansion of maggot distribution to the Gulf Cooperation Council (GCC) region [7]. - The company is committed to keeping shareholders updated on key developments through timely disclosures and filings [5]. Company Background - Cuprina Holdings is based in Singapore and specializes in the development and commercialization of innovative products for chronic wound management, utilizing materials derived from natural sources [6].

Core Insights - Cuprina Holdings has appointed Dr. Ronald A. Sherman as Medical and Scientific Director, effective September 2025, enhancing its expertise in medical maggot therapies [1][3] - The company has secured a licensing agreement for the FDA clearance to market Lucilia sericata Medical MaggotsTM, allowing it to manufacture and distribute these maggots for maggot debridement therapy (MDT) in the U.S. [2][4] - Cuprina is updating its FDA submission for another species of medical maggots, Lucilia cuprina, which could lead to holding two FDA clearances for different maggot species in MDT [3][4] Company Overview - Cuprina Holdings is a Singapore-based biomedical and biotechnology company focused on developing products for chronic wound management and the health and beauty sectors [10] - The company aims to utilize materials from natural sources to create innovative wound care products that meet international standards [10] Market Potential - The U.S. market for maggot debridement therapy was valued at $13.9 million in 2024 and is projected to grow at a CAGR of 10.1% to reach $24.8 million by 2030, driven by the increasing prevalence of chronic wounds and demand for minimally invasive treatments [9]